Session: SAT 834-867-Islet Biology
Bench to Bedside
Poster Board SAT-867
Background: Mesenchymal stem cells (MSCs) are multipotent stem cells with immunomodulatory properties. In this study, we aimed to assess the safety and efficacy of MSCs transplantation in treatment of type 1 diabetes.
Methods: This clinical trial was performed on 23 type 1 diabetic patients aged 5-30 years. The patients had no serious medical diseases or operations with no history of DKA and acute infectious diseases and their fasting blood glucose levels (FBS) were less than 200 mg/dL. Anti glutamic acid decarboxylase test (Anti-GAD) was done for the diagnosis of type 1 diabetes. Culture expanded autologus mesenchymal cells were injected at the dosage of 2 million MSCs/kg .Patients who were still insulin dependent 6 months after the first injection, underwent a second injection of MSCs. Blood glucose and HbA1c levels were monitored throughout the study. No immunosuppressive agents were administered in the patients before and after the transplantation.
Results: No side effects were observed in the patients 19 months after the transplantation. The initial results indicated that 2 patients became insulin- independent within the 6 months after the first injection. In the group which underwent the second injection (n=21), two patients became insulin-free for 2 months but insulin-dependence relapsed after this period. No improvements in insulin dependency were observed in the rest of the patients in this group (n=19). One patient is still insulin free 19 months after the procedure with only one session of MSCs injection.
Conclusion: The findings of this study demonstrated that MSCs transplantation may be considered as a novel curative treatment option for type 1diabetes the near future. However, clinical trials with larger cohorts and long- term follow-ups are essential to demonstrate the safety and effectiveness of this novel treatment option.
Nothing to Disclose: BL, EN, KAM, NM, PA, BN, AG
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters